| Product Name | Lanreotide Acetate Peptide |
| Full Chemical Name | 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate |
| CAS Number | 127984-74-1 |
| Molecular Formula | C₅₄H₆₉N₁₁O₁₀S₂ · xC₂H₄O₂ |
| Appearance | Solid powder |
| Molecular Weight | 1,096.32 g/mol |
| Melting Point | 180-185°C |
| Purity | ≥98% (HPLC) |
| Peptide Type | Cyclic octapeptide (8 amino acids) |
| Solubility | Water:Not reported for research grade;DMSO:Slightly soluble (125 mg/mL per TargetMol) |
| Storage Conditions | -20°C, protect from moisture and light |
| Research Use | For research use only; not for human therapeutic use without authorization |
Products Description
What Is Lanreotide Acetate Peptide?
Lanreotide Acetate is a synthetic cyclic octapeptide analogue of somatostatin (a naturally occurring hormone that inhibits the release of various other hormones). It functions as a somatostatin receptor agonist, primarily targeting the somatostatin receptor subtypes SSTR2 and SSTR5.
Lanreotide is a cyclic octapeptide with a disulfide bridge between two cysteine residues, forming a ring structure.The peptide sequence includes: 3-(2-Naphthalenyl)-D-alanine, cysteine, tyrosine, D-tryptophan, lysine, valine, cysteine, and threoninamide.
Applications Of Lanreotide Acetate Peptide
Lanreotide acetate is an FDA-approved prescription medication for acromegaly, GEP-NETs, and carcinoid syndrome. It should only be used under medical supervision for approved indications. Off-label uses should be supported by appropriate clinical evidence and institutional approval. Research-grade lanreotide is intended for research use only and not for clinical diagnostic or therapeutic purposes without appropriate regulatory authorization.
| Application Category | FDA Status | Key Indication | Dosage (every 4 weeks) | Evidence Level |
|---|---|---|---|---|
| Acromegaly | Approved | Inadequate response to surgery/radiotherapy | 60-120 mg | Phase |
| GEP-NETs | Approved | Unresectable, well-differentiated, locally advanced/metastatic | 120 mg | Phase |
| Carcinoid Syndrome | Approved (orphan drug) | Reduces rescue therapy frequency | 120 mg | Orphan designation |
| Angiodysplasias | Off-label (NHS) | Recurrent anemia | Per formulary | NHS approved |
| Polycystic Liver Disease | Off-label (NHS) | Severe symptomatic ADPKD | Case basis | NHS approved |
| Cancer Research | Preclinical | Prostate cancer, pituitary adenoma | Variable | In vitro/in vivo |
Benefits Of Lanreotide Acetate Peptide
1.Clinical Benefits for Acromegaly
Lanreotide is FDA-approved for the long-term treatment of acromegaly in patients who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy.
| Benefit Category | Description |
| GH Level Reduction | Inhibits growth hormone (GH) secretion from pituitary adenomas via SSTR2 activation |
| IGF-1 Normalization | Reduces insulin-like growth factor-1 levels-the key biomarker for acromegaly control |
| Sustained Control | Monthly dosing provides continuous hormone suppression between injections |
2.Antiproliferative Benefits for Neuroendocrine Tumors (GEP-NETs)
2.1Lanreotide is FDA-approved for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
2.2The landmark CLARINET trial demonstrated the antiproliferative benefit of lanreotide depot
| Endpoint | Lanreotide Depot (120 mg) | Placebo | Benefit |
| Median PFS | Not reached | 18.0 months | Significant improvement |
| Risk Reduction | Hazard ratio: 0.47 (95% CI: 0.30–0.73) | - | 53% lower risk of progression or death |
| 96-Week PFS Rate | 65% | 33% | Double the progression-free rate |
| CgA Reduction (≥50%) | 42% of patients | 5% of patients | 8.4x improvement in biomarker response |
Benefits vs. Risks
While lanreotide offers significant therapeutic benefits, healthcare providers should be aware of potential adverse effects.
| Adverse Reaction | Incidence | Population |
|---|---|---|
| Diarrhea | 37% | Acromegaly |
| Cholelithiasis (gallstones) | 20% | Acromegaly |
| Abdominal pain | 19% | Acromegaly |
| Injection site reactions | 9% | Acromegaly |
| Headache | ≥5% vs placebo | Carcinoid syndrome |
| Hyperglycemia | >10% | GEP-NET |
Signature Record
Packing &Shipping
CONTACT PAGE
1.Inquiry methods：
Email:alice@xaheshun.com
Whatspp:+8618509260106
Online instant messaging
2.Contact Information：
Name：Alice
Telephone :+8618509260106
Email:alice@xaheshun.com
FAQ
Q: How should Lanreotide Acetate be stored?
A: For Powder:Store at -20°C (long-term); protect from moisture and light.
For Solution:Not recommended for long-term storage; prepare fresh.
Q: What is the typical pricing and stock availability for research grade?
A:Research-grade products are for research and development use only, not for human therapeutic use -6. Many suppliers require new customer onboarding and do not ship to residential addresses.
Q: What is your production scale for Lanreotide Acetate, and can you accommodate both R&D and commercial volumes?
A: We operate advanced solid-phase and liquid-phase hybrid peptide synthesis platforms. We offer flexible scale capability, supplying milligram to gram lots for formulation R&D and clinical trials, and multi-kilogram commercial batches per year. This seamless scalability eliminates the risk of supply chain disruption during your product's lifecycle transition from clinical phases to commercial launch.
Q: What are the standard specifications for acetate content and peptide content in your Lanreotide Acetate?
A:nsuring consistency in salt-forming ratios is critical for formulation stability. Our standard specification targets an acetate (counter-ion) content of 9.0% to 13.0% and a net peptide content of ≥85.0% (determined by amino acid analysis or HPLC). These parameters can be tightly optimized and customized to match your specific innovator bio-equivalence (sameness) requirements.
Q: What are the recommended storage conditions, and how do you secure global cold-chain transit for Lanreotide Acetate?
A: Lanreotide Acetate API is a hygroscopic peptide and should be stored in tightly sealed containers at -20 ℃±5℃, protected from light and moisture. For international logistics, we utilize validated, temperature-monitored cold-chain shipping containers (dry ice or 2 ℃ to 8 ℃ gel packs) with active data loggers to guarantee that product integrity is maintained continuously from our warehouse to your facility.
Hot Tags: lanreotide acetate peptide, China lanreotide acetate peptide manufacturers, suppliers, factory, ALA Powder for Skin Aging, Methylene Blue for Cell Research, Pantethine for Hormonal Balance, Tetrahydrocurcumin for Joint Health, Tianeptine Sodium Salt for Emotional Well being, Zinc Bacitracin for Wound Disinfection
